Itai Levi

Beersheba, D, Israel

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 42 publications

Real-World Outcomes of Venetoclax-Based Therapy in Treatment-Naïve and Relapsed/Refractory CLL/SLL: Interim Results From the Prospective REVEAL Study.

Real-World Outcomes of Venetoclax-Based Therapy in Treatment-Naïve and Relapsed/Refractory CLL/SLL: Interim Results From the Prospective REVEAL Study.

Journal: American journal of hematology
Published: April 09, 2026

Real-world outcomes of BrECADD therapy in advanced-stage classical Hodgkin lymphoma: A multicentre retrospective study.

Real-world outcomes of BrECADD therapy in advanced-stage classical Hodgkin lymphoma: A multicentre retrospective study.

Journal: British journal of haematology
Published: March 31, 2026

Single-agent mosunetuzumab in older or unfit patients with previously untreated DLBCL: results of a phase 1/2 trial.

Single-agent mosunetuzumab in older or unfit patients with previously untreated DLBCL: results of a phase 1/2 trial.

Journal: Blood neoplasia
Published: March 20, 2026

Positive anti-neutrophil antibodies test in autoimmune neutropenia experience from single center cohort.

Positive anti-neutrophil antibodies test in autoimmune neutropenia experience from single center cohort.

Journal: Acta haematologica
Published: February 04, 2026

Identifying Clones in Myelodysplastic Syndromes by Using Single-Cell RNA Sequencing.

Identifying Clones in Myelodysplastic Syndromes by Using Single-Cell RNA Sequencing.

Journal: Hematological oncology
Published: May 17, 2025

Outcomes of non-COVID-19 critically ill patients with hematologic malignancies a 10-year single-center retrospective analysis.

Outcomes of non-COVID-19 critically ill patients with hematologic malignancies a 10-year single-center retrospective analysis.

Journal: Leukemia & lymphoma
Published: September 12, 2024

Case report: VEXAS syndrome with excellent response to treatment with azacitidine.

Case report: VEXAS syndrome with excellent response to treatment with azacitidine.

Journal: Annals of hematology
Published: August 22, 2024

Trial eligibility, treatment patterns, and outcome for venetoclax-based therapy in AML: a prospective cohort study.

Trial eligibility, treatment patterns, and outcome for venetoclax-based therapy in AML: a prospective cohort study.

Journal: Blood advances
Published: June 17, 2024

Ibrutinib With Bendamustine and Rituximab for Treatment of Patients With Relapsed/Refractory Aggressive B-Cell Lymphoma.

Ibrutinib With Bendamustine and Rituximab for Treatment of Patients With Relapsed/Refractory Aggressive B-Cell Lymphoma.

Journal: Hematological oncology
Published: March 05, 2024

MDS-Related Anemia Is Associated with Impaired Quality of Life but Improvement Is Not Always Achieved by Increased Hemoglobin Level.

MDS-Related Anemia Is Associated with Impaired Quality of Life but Improvement Is Not Always Achieved by Increased Hemoglobin Level.

Journal: Journal of clinical medicine
Published: August 04, 2023

Aspacytarabine for the treatment of patients with AML unfit for intensive chemotherapy: a phase 2 study.

Aspacytarabine for the treatment of patients with AML unfit for intensive chemotherapy: a phase 2 study.

Journal: Blood advances
Published: June 12, 2023

Treatment with obinutuzumab leads to worse outcomes in haematological patients diagnosed with Omicron variant COVID-19.

Treatment with obinutuzumab leads to worse outcomes in haematological patients diagnosed with Omicron variant COVID-19.

Journal: British journal of haematology
Published: May 22, 2022
Showing 1-12 of 42

Last Updated: 09/26/2026